Site icon pharmaceutical daily

Diplomat gets distribution of Novartis’s new cancer drug

Diplomat

Diplomat

Diplomat Pharmacy will distribute Novartis’s newly approved breast cancer drug Kisqali (ribociclib) as a first-line treatment for postmenopausal women with a serious form of the disease.

FDA on Tuesday approved Novartis’s breast cancer drug in combination with an aromatase inhibitor as initial endocrine-based therapy for treatment of postmenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer.

According to the American Cancer Society, breast cancer is the second most common cancer among American women, with more than 315,000 diagnoses expected in 2017.

Exit mobile version